The new trial combines volatility ranked Med followed by an RTP away from 95.96% and you may includes maximum wins to step one,500x. It launched throughout the 2022 while offering participants a volatility level of Med-High an RTP value of 95.4% and best wins as much as a ceiling away from 2,400x your share.